LifeSci Capital analyst Rami Katkhuda has maintained their neutral stance on VYNE stock, giving a Hold rating on July 31.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Rami Katkhuda has given his Hold rating due to a combination of factors surrounding VYNE Therapeutics’ current financial and clinical position. The company reported a cash position of $39.6 million, which, along with their cost reduction strategies, is expected to sustain operations until the first half of 2027. However, the clinical progress presents a mixed picture.
The lifting of the FDA hold on VYN202 for female patients is a positive development, offering encouraging proof-of-concept data for its potential in autoimmune indications. Yet, the requirement for further toxicology studies before male dosing can commence adds a layer of uncertainty. Additionally, the Phase IIb study of repibresib did not achieve its primary endpoints, leading to the termination of the trial’s extension phase and the search for external partnerships. These mixed clinical outcomes, coupled with a significant short interest of 15.4%, contribute to the Hold rating as the company navigates these challenges.
Katkhuda covers the Healthcare sector, focusing on stocks such as VYNE Therapeutics, Dianthus Therapeutics, and Vera Therapeutics. According to TipRanks, Katkhuda has an average return of 13.1% and a 43.62% success rate on recommended stocks.
In another report released on July 31, BTIG also downgraded the stock to a Hold with a $0.00 price target.